|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 新城疫病毒某水禽分离株经鸡体传代后由非致病型转变为速发型的研究显示文摘最近 ,一株无毒力的新城疫病毒 (NDV)在鸡体内繁殖时 ,变成了强毒株。但至今尚未能证实 ,经鸡体传代的野生水禽新城疫病毒是否也具有变成速发型毒株的能力。为了通过实验证明从水禽中分离的非致病型NDV可以转变为速发型病毒 ,我们通过在鸡体内传播鹅源性无毒力株 ,经气囊接种连续传代 9次 ,随后再在鸡脑内传代 5次。结果显示 ,该病毒的毒力变得很强 ,致死率可达 1 0 0 %。通过致病性试验证实 ,其具有典型的速发型病毒特征 ;融合蛋白裂解位点的序列分析表明 ,原始的分离株含有无毒力型毒株共有的裂解序列 :E_R_Q_E_R/L,而通过鸡体反复传代后 ,该序列变为致病性毒株共有的序列 :K_R_Q_K_R/F。这些结果表明 ,野生水禽中自然存在的无毒力毒株 ,具有无毒力株相应的序列 ,但当其在鸡群中传播时 ,则具有变成高致病性病毒的能力。同时研究表明 ,鸡体提供了该病毒从非致病型向致病型转变的选择机制。 | 于圣青 丁铲 NORIKO KISHIDA HIROSHI ITO HIROSHI KIDA KOICHI OTSUKI YOSHIHIRO KAWAOKA TOSHIHIRO ITO | 2003 | 中国预防兽医学报2003，25，1： | 32 |
| 2 | H5N1 influenza viruses: outbreaks and biological properties显示文摘流行性感冒的所有已知的子类型 A 病毒在野水鸟被维持,这些病毒的自然水库。流行性感冒 A 病毒被孤立从许多有改变病态和死亡率的动物种类。更重要地,流行性感冒 A 病毒与潜在地致命的结果在人引起呼吸疾病。在人的本地或全球的爆发被过量住院和死亡典型地描绘。在 1997, H5N1 子类型的高度病原的鸟的流行性感冒病毒在传给人的香港出现了,导致由鸟的流行性感冒病毒感染的人的死亡的首先记录的盒子。在越南,印度尼西亚,和泰国在家禽在 2003 年 7 月开始的新爆发,和高度病原的鸟的 H5N1 流行性感冒病毒后来在整个亚洲并且进欧洲和非洲传播了。这些病毒继续与高死亡率感染人并且引起隐约可见的世界范围的担心流行。而且, H5N1 病毒爆发在整个亚洲在家禽工业上有破坏效果。因为 H5N1 病毒爆发看起来从南部的中国发源,我们这里在中国检验 H5N1 流行性感冒病毒,与他们的生物性质上的一个重音。 | Gabriele Neuman Hualan Chen George F Gao Yuelong Shu Yoshihiro Kawaoka | 2010 | Cell Research2010，20，1： | 19 |
| 3 | An infectious disease of ducks caused by a newly emerged Tembusu virus strain in mainland China显示文摘 | Pixi Yan Youshu Zhao Xu Zhang Dawei Xu Xiaoguang Dai Qiaoyang Teng Liping Yan Jiewen Zhou Xiwen Ji Shumei Zhang Guangqing Liu Yanjun Zhou Yoshihiro Kawaoka Guangzhi Tong Zejun Li | 2011 | Virology2011，，1： | 5 |
| 4 | Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases显示文摘The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC). Systemic gemcitabine chemotherapy seems effective in many cancers. We report the results of combination therapy with systemic gemcitabine, intra-arterial low-dose cisplatin and 5-FU (GEMFP). Seven patients with non-resectable advanced HCC were treated with GEMFP. One course of chemotherapy consisted of daily intra-arterial cisplatin (20 mg/body weight/hour on d 1, 10 mg/body weight per 0.5 h on d 2-5 and 8-12), followed by 5-FU (250 mg/body weight per 5 h on d 1-5 and 8-12) via an injection port. Gemcitabine at 1000 mg/m2 was administered intravenously at 0.5 h on d 1 and 8. The objective response was 57%. The response to GEMFP was as follows: complete response (no patients), partial response (four patients), stable disease (three patients), and progressive disease (no patients). The median survival period was 8 mo (range, 5-55). With regard to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 3 or 4 adverse reactions, seven (100%), seven, six (86%) and one (14%) patients developed leukopenia, neutropenia, thrombocytopenia and anemia, respectively. GEMFP may potentially be effective for non- resectable advanced HCC, but it has severe hematologic toxicity. | Kiminori Uka Hiroshi Aikata Shintaro Takaki Tomokazu Kawaoka Hiromi Saneto Daiki Miki Shoichi Takahashi Naoyuki Toyota Katsuhide Ito Kazuaki Chayama | 2008 | World Journal of Gastroenterology2008，14，16： | 4 |
| 5 | 共沉淀法制备Al_2O_3-YAG复相陶瓷及其显微结构研究显示文摘用共沉淀法制备了Al2O3-YAG复合粉体,YAG的结晶温度在1000℃左右.共沉淀法 制备的Al2O3-YAG复合粉体经1550℃热压烧结,获得致密烧结体,YAG的加入量对烧结温度 的影响不大. Al2O3-5vol%YAG复合材料的抗弯强度为604MPa,断裂韧性为5.0MPam1/2; Al2O3-25vol%YAG复合材料的抗弯强度为611MPa,断裂韧性为45MPam1/2.所有这些数据 都高于单相Al2O3陶瓷的力学性能,说明YAG的加入有利于A12O3陶瓷力学性能的提高. 通过显微结构观察发现:大的YAG颗粒位于Al2O3晶界上,小的YAG颗粒位于Al2O3晶粒 内.在 Al2O3-5vol%YAG复合材料中,许多小的白色区域存在于 Al2O3晶粒内,这可能和较低 的Y2O3含量有关. | 王宏志 高濂 李炜群 Hirokazu Kawaoka Koichi Niihara | 2001 | 无机材料学报2001，16，1： | 4 |
| 6 | Effects of a 24-week course of interferon-αtherapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma显示文摘AIM:To assess whether a 24-wk course of interferon (IFN)could prevent hepatocellular carcinoma(HCC) recurrence and worsening of liver function in patients with hepatitis C virus(HCV)-infected patients after receiving curative treatment for primary HCC. METHODS:Outcomes in 42 patients with HCV infection treated with IFN-α,after curative treatment for primary HCC(IFN group),were compared with 42 matched curatively treated historical controls not given IFN(non- IFN group). RESULTS:Although the rate of initial recurrence did not differ significantly between IFN group and non-IFN group (0%,44%,61%,and 67% vs 4.8%,53%,81%,and 87% at 1,3,5,and 7 years,P=0.153,respectively), IFN group showed a lower rate than the non-IFN group for second recurrence(0%,10.4%,28%,and 35% vs 0%,30%,59%,and 66% at 1,3,5 and 7 years, P=0.022,respectively).Among the IFN group,patients with sustained virologic response(SVR)were less likely to have a second HCC recurrence than IFN patients without an SVR,or non-IFN patients.Multivariate analysis identified the lack of SVR as the only independent risk factor for a second recurrence,while SVR and Child-Pugh class A independently favored overall survival. CONCLUSION:Most intrahepatic recurrences of HCV- related HCC occurred during persistent viral infection. Eradication of HCV is essential for the prevention of HCC recurrence and improvement of survival. | Soo Cheol Jeong Hiroshi Aikata Yoshio Katamura Takahiro Azakami Tomokazu Kawaoka Hiromi Saneto Kiminori Uka Nami Mori Shintaro Takaki Hideaki Kodama Koji Waki Michio Imamura Hiroo Shirakawa Yoshiiku Kawakami Shoichi Takahashi Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，40： | 3 |
| 7 | Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma显示文摘AIM: To assess the efficacy of low-dose intermittent interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related compensated cirrhosis who had received curative treatment for primary hepatocellular carcinoma (HCC). METHODS: We performed a prospective case controlled study. Sixteen patients received 3 MIU of natural IFN- alpha intramuscularly 3 times weekly for at least 48 wk (IFN group). They were compared with 16 matched historical controls (non-IFN group). RESULTS: The cumulative rate of first recurrence of HCC was not significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 68.6% vs 80% at 1- and 3-year, P = 0.157, respectively). The cumulative rate of second recurrence was not also significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 35.9% vs 67% at 1- and 3-year, P = 0.056, respectively). Although the difference in the Child-Pugh classification score between the groups at initial treatment of HCC was not signifi cant, the score was signifi cantly worse at the time of data analysis in the non-IFN group than IFN group (7.19 ± 1.42 vs 5.81 ± 0.75, P = 0.0008). The cumulative rate of deviation from objects of any treatment for recurrentHCC was also higher in the non-IFN group than IFN group (6.7% and 27% vs 0 and 0% at 1- and 3-year, P = 0.048, respectively). CONCLUSION: Low-dose intermittent IFN-alpha therapy for patients with HCV-related compensated cirrhosis after curative HCC treatment was effective by making patients tolerant to medical or surgical treatment for recurrent HCC in the later period of observation. | Soocheol Jeong Hiroshi Aikata Yoshio Katamura Takahiro Azakami Tomokazu Kawaoka Hiromi Saneto Kiminori Uka Nami Mori Shintaro Takaki Hideaki Kodama Koji Waki Michio Imamura Hiroo Shirakawa Yoshiiku Kawakami Shoichi Takahashi Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，39： | 2 |
| 8 | Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis显示文摘 | Yoshio Katamura Hiroshi Aikata Shintaro Takaki Takahiro Azakami Tomokazu Kawaoka Koji Waki Akira Hiramatsu Yoshiiku Kawakami Shoichi Takahashi Masahiro Kenjo Naoyuki Toyota Katsuhide Ito Kazuaki Chayama | 2009 | Journal of Gastroenterology2009，，5： | 2 |
| 9 | Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma显示文摘 | Yohji Honda Tomoki Kimura Hiroshi Aikata Tomoki Kobayashi Takayuki Fukuhara Keiichi Masaki Takashi Nakahara Noriaki Naeshiro Atsushi Ono Daisuke Miyaki Yuko Nagaoki Tomokazu Kawaoka Shintaro Takaki Akira Hiramatsu Masaki Ishikawa Hideaki Kakizawa Masahiro | 2013 | J Gastroenterol Hepatol2013，，3： | 2 |
| 10 | Emergence and pandemic potential of swine -origin H1N1 influenza virus显示文摘 | Nenmana G Noda T Kawaoka Y | 2009 | Nature2009，459，7249： | 1 |
| 11 | Do hemagglutinin genes of highly pathogenic avian in显示文摘 | Rohm C Horimoto T Kawaoka Y | 1995 | Virology1995，209，2： | 1 |
| 12 | Survey of the hemagglutinin(HA) cleavage site sequence of H5 and H7 avian influenza viruses : amino acid sequence at the HA cleavage site as a marker of pathogenicity potential 显示文摘 | Senne D A Panigrahy B Kawaoka Y | 1996 | Avian Dis1996，40，2： | 1 |
| 13 | The surface glycoproreins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties 显示文摘 | Matrosovich M Zhou N Kawaoka Y | 1999 | Virology1999，73，： | 1 |
| 14 | Avian-to-human transmission of the PBI gene of influenza A viruses in the 1957 and 1968 pandemics显示文摘 | Kawaoka Y Krauss S Webster R G | 1989 | Journal of virology1989，63，11： | 1 |
| 15 | Hypersensitivity Reactions to Transcatheter Chemoembolization with Cisplatin and Lipiodol Suspension for Unresectable Hepatocellular Carcinoma显示文摘 | Tomokazu Kawaoka Hiroshi Aikata Yoshio Katamura Shintaro Takaki Koji Waki Akira Hiramatsu Shoichi Takahashi Masashi Hieda Hideaki Kakizawa Kazuaki Chayama | 2010 | Journal of Vascular and Interventional Radiology2010，，8： | 1 |
| 16 | The origins of new pandem-ic viruses:The acquisition of new host ranges by ca-nine parvovirus and influenza A viruses显示文摘 | Kawaoka Y | 2005 | Annu Rev Microbiol2005，59，： | 1 |
| 17 | Wild ducks are he reservoir for only a limited number of influenza A subtype显示文摘 | Sharp G Kawaoka Y Wright S M | 2005 | Epidemiol Infect2005，110，： | 1 |
| 18 | Protective immunity against avian influenza induced by a fowlpox virus recombinant显示文摘 | Taylor J Weinberg R Kawaoka Y | 1988 | Vaccine1988，，6： | 1 |
| 19 | Evolutionary pathways of the PA genes of influenza A viruses显示文摘 | Okazaki K Kawaoka Y Webster R G | 1989 | Virology1989，172，2： | 1 |
| 20 | Efficacy oflamivudine therapy in elderly patients with chronic hepatitis B infection 显示文摘 | Kawaoka T Suzuki F Akuta N etal | 2007 | J Gastroenterol2007，42，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员